Abstract
Acute myeloid leukemia (AML) is a complex hematological cancer that mainly affects elderly patients (over 60 years old) and these patients are the ones that have worst response to current treatments. Thus, there is a great need for new therapeutic alternatives for this cancer. In the last decade, the BRD4 (bromodomain-containing protein 4) has been identified as one of the main possible t…